Imatinib Mesylate is Effective for Patients Not Only with Chronic Myeloid Leukemia, but Also Rheumatoid Arthritis.
- Author:
Hyun Jun JUNG
1
;
Dae Ho KIM
;
Ran SONG
;
Seung Jae HONG
;
Hyung In YANG
;
Wan Kyu EO
;
Sang Hoon LEE
Author Information
1. Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea. boltaguni@yahoo.co.kr
- Publication Type:Case Report
- Keywords:
Chronic myelogenous leukemia;
Imatinib;
Rheumatoid arthritis
- MeSH:
Arthritis, Rheumatoid;
Benzamides;
Cytokines;
Humans;
Inflammation;
Korea;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates;
Middle Aged;
Piperazines;
Protein-Tyrosine Kinases;
Pyrimidines;
Tyrosine;
Imatinib Mesylate
- From:Korean Journal of Medicine
2012;83(3):405-410
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Synovial tissue proliferation and inflammation are regarded as possible causes of rheumatoid arthritis. Activation of tyrosine kinase by numerous cytokines and BCR-ABL translocation contribute to synovial tissue inflammation and the development of rheumatoid arthritis, respectively. Imatinib is a tyrosine kinase-blocking agent that is widely used for treating chronic myeloid leukemia. We found several interesting case reports of patients with refractory rheumatoid arthritis who entered remission after initiating imatinib therapy. However, only one case report on treating rheumatoid arthritis with imatinib was found in Korea. Here, we describe the case of a 50-year-old man who showed clinical remission of rheumatoid arthritis and chronic myeloid leukemia after receiving 3 months of imatinib therapy.
